Bizarre Patents
Combination Beverage Container and Spittoon
A combination beverage container and spittoon includes a bottom portion including outer wall and a first inner wall defining a spittoon space.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8119773 | Compositions and methods for facilitating heme-iron export from cells The invention provides a high affinity heme-binding agent, which can be provided in the form of a pharmaceutical composition that includes, optionally, a pharmaceutically acceptable carrier. The heme-binding agent can be used in a method of facilitating heme-iron ex... | 02/21/2012 |
| 8084581 | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus A method heat treatment of cross-linked hemoglobin solutions including polymeric hemoglobin is disclosed. The method involves contacting the hemoglobin solution with a high temperature short time heat treatment apparatus. The high temperature short time process ther... | 12/27/2011 |
| 8048856 | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesire... | 11/01/2011 |
| 7999076 | Use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium The present invention relates to the use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium. Advantageously, the extracellular hemoglobin is obtained from Annelids.... | 08/16/2011 |
| 7989593 | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof A high temperature-stable and highly purified cross-linked (optionally ≧70% β-β linked) tetrameric hemoglobin with high efficiency of oxygen delivery suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of h... | 08/02/2011 |
| 7932356 | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesire... | 04/26/2011 |
| 7803912 | Increasing the stability of recombinant adult human apohemoglobin The disclosure relates to recombinant adult human apohemoglobin (apo-rHb) in which the stability has been increased by replacement of an amino acid with a counterpart from another organism, such as a deep sea diving mammal. This mutated apo-rHb may be more stable an... | 09/28/2010 |
| 7795401 | Modified hemoglobin with allosteric effector conjugated The present invention relates generally to a modified hemoglobin with an allosteric effector conjugated which is capable of dynamically regulating the efficiency of oxygen release. The hemoglobin composition provided in the present invention is utilizing maleimide-P... | 09/14/2010 |
| 7678888 | Stable oxidation resistant powdered hemoglobin, methods of preparing same, and uses thereof The present invention provides oxygenated hemoglobins in powdered form and methods of preparing a powdered form of a protein, such as hemoglobin, which comprise (a) mixing a solution of the protein with inulin, and optimally with a reducing sugar such as glucose or ... | 03/16/2010 |
| 7538193 | NO-modified hemoglobins and uses therefor S-nitrosohemoglobin can liberate NO by transfer to a low molecular weight thiol in the circulatory system, allowing the delivery of NO to the tissues. The effect of administering isolated S-nitrosohemoglobin and low molecular weight thiol to a mammal is to increase ... | 05/26/2009 |
| 7459535 | Method of forming a polymerized hemoglobin solution from stabilized hemoglobin A stabilized hemoglobin solution is contacted with polymerizing agent. The stabilized hemoglobin solution includes stabilized tetrameric hemoglobin. At least a portion of the stabilized tetrameric hemoglobin is polymerized by reaction with the polymerizing agent, th... | 12/02/2008 |
| 7435795 | Stabilized hemoglobin solutions A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system furt... | 10/14/2008 |
| 7427663 | Cardio myopeptidin, the production and the use thereof The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%... | 09/23/2008 |
| 7411044 | Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer t... | 08/12/2008 |
| 7411038 | Artificial red blood cells An artificial red blood cells are disclosed comprising a thin film encapsulating a core, the core comprising hemoglobin, wherein the film comprises a plurality of layers of polypeptides, opposing layers comprising alternating oppositely charged polypeptides, and whe... | 08/12/2008 |
| 7381797 | Stabilization of HOunder alkaline conditions for use in luminescence, fluorescence and colorimetric assays for enhanced detection of peroxidase type assays The invention relates to stannous halide stabilized and/or enhanced alkaline solutions to be used in combination with colorimetric, luminescent and fluorescent assays. The buffered solutions stabilize hydrogen peroxide at a pH greater than 7.0 and preferably greater... | 06/03/2008 |
| 7358338 | Heme peptide A novel heme peptide and a method for producing the same are disclosed. The invention provides a peptide with a potent NO-scavenging ability which can be used in capturing/quantifying NO and can be used as a diagnostic agent, prophylactic agent or therapeutic... | 04/15/2008 |
| 7329641 | Blood substitutes The functional characteristics of heme proteins can be modified to produce hemoglobins that can be used as blood substitutes in different therapeutic applications. Stable polymers of tetrameric hemoglobin, and of myoglobin molecules, are provided for use in the bloo... | 02/12/2008 |
| 7323442 | Agents for alleviating symptoms accompanied by inflammation The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, asc... | 01/29/2008 |
| 7307150 | Dextran-hemoglobin conjugates as blood substitutes An hemoglobin (Hb)-Dextran (Dx) conjugate having a molecular weight between 50 kd and 500 kD provides a blood substitute that results in acceptable erythrocyte sedimentation rate (ESR) and excretion rate (EXC) values. DxHb conjugates of the invention can be used for... | 12/11/2007 |
| 7291592 | Method for treating patients with massive blood loss Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution. ... | 11/06/2007 |
| 7291122 | Hemofiltration methods for treatment of diseases in a mammal A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal ... | 11/06/2007 |
| 7285544 | Use of nitroxides in treating skin disease Methods of treating inflammatory skin diseases such as rosacea, atopic dermatitis, contact dermatitis, drug eruptions, psoriasis, seborrheic dermatitis, connective tissue diseases, autoimmune disorders, urticaria or hives, and inflammation associated with skin infec... | 10/23/2007 |
| 7282567 | Monoclonal antibody hPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope o... | 10/16/2007 |
| 7273924 | Antibodies to the ED-B domain of fibronectin, their construction and uses A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN). ... | 09/25/2007 |
| RE39789 | Tumor therapy Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and cytokines may be included to enhance the immune response. The composit... | 08/21/2007 |
| 7252824 | Anti-neovasculature preparations for cancer Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of m... | 08/07/2007 |
| 7238777 | Agents for adsorption and bridging for adenovirus The object of the present invention is to provide an agent for specific adsorption of type 5 adenoviral vector to undifferentiated blood cells which enables infection with a viral concentration that does not impart toxicity to undifferentiated blood cells, without r... | 07/03/2007 |
| 7238786 | Monoclonal antibody cPAM4 This invention relates to monovalent and multivalent, monospecific antibodies and to monovalent and multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen ... | 07/03/2007 |
| 7235639 | Hemoglobin conjugates The invention provides a conjugate of hemoglobin and a nucleic acid cross-linking agent. ... | 06/26/2007 |
| 7232888 | Antibodies against tumor surface antigens The present invention relates to improved antibodies against tumor surface antigens and their use in the treatment of tumors. Of particular interest are highly stable, humanized, high affinity antibodies against carcinoembryonic antigen (CEA), especially the antibod... | 06/19/2007 |
| 7220552 | Bifunctional molecules and their use in the disruption of protein-protein interactions Bifunctional inhibitor molecules and methods for their use in the inhibition of protein—protein interactions are provided. The subject bifunctional inhibitor molecules are conjugates of a target protein ligand and a blocking protein ligand, where these two moietie... | 05/22/2007 |
| 7217795 | Tumor suppressor designated TS10q23.3 A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region ... | 05/15/2007 |
| 7217796 | Neutralizing human anti-IGFR antibody The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing th... | 05/15/2007 |
| 7211560 | Reduced side-effect hemoglobin compositions The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hype... | 05/01/2007 |
| 7202340 | No-modified hemoglobins and uses therefor Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated... | 04/10/2007 |
| 7202346 | Antibodies to non-shed Muc1 and Muc16, and uses thereof The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellula... | 04/10/2007 |
| 7202077 | Methods for enhancing the translation and expression of recombinant proteins The increased use of nucleotide sequence data mining techniques has amplified the demand for efficient methods of producing recombinant proteins in prokaryotic cells. A strategy is provided for enhancing the synthesis of recombinant amino acid sequences by improving... | 04/10/2007 |
| 7202341 | Stabilized hemoglobin solutions A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system furt... | 04/10/2007 |
| 7195923 | Ratiometric determination of glycated protein The present invention provides methods for determining a ratio of an amount of a glycated form of a protein to a total amount of the protein in a sample containing the glycated protein, the glycosylated protein, or the glycoprotein. The method incorporates lateral f... | 03/27/2007 |
